5+ hour, 8+ min ago  (101+ words) Enhancing health and delivering better outcomes for 5. 6 million people by improving access to medicine through climate-resilient supply chain innovation. Budget: 906 million yen IMC's Pharmaceutical Information Management System (PIMS) directly addresses these challenges by tracking medicines and supplies to the patient…...

3+ week, 1+ day ago  (380+ words) Planetary health and human health are inseparable. When air is polluted, water is scarce and ecosystems are stressed, the effects are felt in communities and across the natural systems we rely on to develop and deliver medicines. That's why we…...

4+ week, 11+ hour ago  (621+ words) How we are driving innovation in packaging design to help patients take their medications safely, effectively and in the way that they have been prescribed. On the face of it, pharmaceutical packaging is simply a bottle, vial or pretty cardboard…...

1+ mon, 1+ week ago  (412+ words) Takeda supports a public-private partnership to manufacture a rare disease medicine'even when only one batch is produced every five years. "Thank you for doing this because you actually saved my granddaughter's life." When John Sisto worked at Takeda's Los Angeles…...

1+ mon, 3+ week ago  (396+ words) Putting our Access to Medicines approach into practice worldwide to expand access in low" and middle"income countries. "Science and technology are advancing at remarkable speed, but the challenge is ensuring these breakthroughs reach the people who need them most....

3+ mon, 3+ day ago  (543+ words) How our global CSR program is equipping the next generation of nurses in low-income countries to lead lasting change in health care. "It was a door opening. It meant I could attend classes with a clear mind, not worrying about…...

2+ mon, 3+ week ago  (448+ words) Since its launch in 2016, the award has recognized 10 outstanding scientists with $2 million in unrestricted funding. The program enters a new chapter this year with a reimagined focus on early-career researchers working in our therapeutic areas of interest: gastrointestinal and inflammatory…...

6+ mon, 1+ week ago  (295+ words) Takeda today announced that as part of a strategic portfolio prioritization process, the company has made the decision to discontinue its cell therapy efforts. Takeda Provides Update on Cell Therapy Research | Takeda Pharmaceuticals OSAKA, Japan and CAMBRIDGE, Massachusetts, October 1, 2025 " Takeda…...

8+ mon, 3+ week ago  (432+ words) Takeda (TSE: 4502/NYSE: TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2 R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the…...